Gaetano Zaccara Dr (University of Florence)
Senior Consultant, 'Agenzia Regionale di Sanità della Toscana, Firenze, Toscana · Italy
Editorial leadership for Journal of Neurological Research And Therapy ISSN 2470-5020
Research interests
- Antiepileptic Drugs
Biography
Dr. Gaetano Zaccara is Senior Consultant at the Agenzia Regionale di Sanità della Toscana, Firenze, Toscana, Italy. He graduated in Medicine at the University of Florence in 1973 and specialized in Psychiatry in 1977 and Neurology in 1982, with subsequent training at the clinical pharmacology unit of the Research Institute "M. Negri" in Milan and the laboratories of neurophysiology at Johns Hopkins University, Baltimore. His main areas of interest are epilepsy and the clinical pharmacology of antiepileptic drugs, and he has performed numerous studies on new antiepileptic agents, serving as principal investigator in several double-blind trials. Dr. Zaccara is author of over 150 publications, including the highly cited network meta-analysis "Antiepileptic monotherapy in newly diagnosed focal epilepsy" (2018), which has been cited 78 times.
Selected publications
- Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis 2018 cited 78×
- Cardiac adverse effects of antiseizure medications 2021 cited 28×
- Drug treatments in patients with cardiac diseases and epilepsy 2020 cited 22×
- Why we prefer levetiracetam over phenytoin for treatment of status epilepticus 2018 cited 21×
- Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy 2018 cited 20×
- Critical Appraisal of Cenobamate as Adjunctive Treatment of Focal Seizures in Adults 2021 cited 15×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JNRT for your work?
This journal is guided by Gaetano Zaccara (Senior Consultant, 'Agenzia Regionale di Sanità della Toscana, Firenze, Toscana) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.